Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.

ABSTRACT:

Objective

To evaluate the utility of amiodarone and its derivative dronedarone as novel drug repositioning candidates in EOC and to determine the potential pathways targeted by these drugs.

Methods

Drug-predict bioinformatics platform was used to assess the utility of amiodarone as a novel drug-repurposing candidate in EOC. EOC cells were treated with amiodarone and dronedarone. Cell death was assessed by Annexin V staining. Cell viability and cell survival were assessed by MTT and clonogenics assays respectively. c-MYC and mTOR/Akt axis were evaluated as potential targets. Effect on autophagy was determined by autophagy flux flow cytometry.

Results

"DrugPredict" bioinformatics platform ranked Class III antiarrhythmic drug amiodarone within the top 3.9% of potential E

SUBMITTER: Belur Nagaraj A 

PROVIDER: S-EPMC6526024 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature